Literature DB >> 9427148

Aspartylglucosaminuria among Palestinian Arabs.

J Zlotogora1, Z Ben-Neriah, B Y Abu-Libdeh, V Sury, M Zeigler.   

Abstract

Aspartylglucosaminuria (AGU) is a rare disorder of glycoprotein metabolism caused by the deficiency of the lysosomal enzyme aspartylglucosaminidase (AGA). AGU is inherited as an autosomal recessive trait and occurs with a high frequency in Finland because of a founder effect. While very few patients with AGU have been reported from non-Finnish origin, we diagnosed the disorder in 8 patients originating from 3 unrelated families, all Palestinian Arabs from the region of Jerusalem. The clinical diagnosis of AGU is often difficult, in particular early in the course of the disease, and most of the patients are diagnosed after the age of 5 years. However, since these patients excrete early large amounts of aspartylglucosamine in urine, biochemical screening is easy by urine chromatography.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427148     DOI: 10.1023/a:1005371802085

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  Oligosaccharides in urine of patients with glycoprotein storage diseases. I. Rapid detection by thin-layer chromatography.

Authors:  R Humbel; M Collart
Journal:  Clin Chim Acta       Date:  1975-04-16       Impact factor: 3.786

2.  Ser72Pro active-site disease mutation in human lysosomal aspartylglucosaminidase: abnormal intracellular processing and evidence for extracellular activation.

Authors:  M Peltola; R Tikkanen; L Peltonen; A Jalanko
Journal:  Hum Mol Genet       Date:  1996-06       Impact factor: 6.150

3.  Eleven new cases of aspartylglucosaminuria.

Authors:  J Palo; K Mattsson
Journal:  J Ment Defic Res       Date:  1970-06

Review 4.  Disease gene mapping in isolated human populations: the example of Finland.

Authors:  A de la Chapelle
Journal:  J Med Genet       Date:  1993-10       Impact factor: 6.318

5.  Detection of heterozygotes for aspartylglucosaminuria (AGU) in cultured fibroblasts.

Authors:  P Aula; S Autio; K Raivio; V Näntö
Journal:  Humangenetik       Date:  1974

Review 6.  Aspartylglycosaminuria: an inborn error of glycoprotein catabolism.

Authors:  C P Maury
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

7.  Aspartylglycosaminuria (AGU). Further aspects on its clinical picture, mode of inheritance and epidemiology based on a series of 57 patients.

Authors:  S Autio; J K Visakorpi; H Järvinen
Journal:  Ann Clin Res       Date:  1973-06

Review 8.  Mutations causing aspartylglucosaminuria (AGU): a lysosomal accumulation disease.

Authors:  E Ikonen; L Peltonen
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

9.  Aspartylglucosaminuria: cDNA encoding human aspartylglucosaminidase and the missense mutation causing the disease.

Authors:  E Ikonen; M Baumann; K Grön; A C Syvänen; N Enomaa; R Halila; P Aula; L Peltonen
Journal:  EMBO J       Date:  1991-01       Impact factor: 11.598

  9 in total
  2 in total

1.  Sleep disturbances in aspartylglucosaminuria (AGU): a questionnaire study.

Authors:  Niki Lindblom; Satu Kivinen; Hannu Heiskala; Maija-Liisa Laakso; Markus Kaski
Journal:  J Inherit Metab Dis       Date:  2006-08-30       Impact factor: 4.982

Review 2.  Sleep and sleep disorders in rare hereditary diseases: a reminder for the pediatrician, pediatric and adult neurologist, general practitioner, and sleep specialist.

Authors:  Natan Gadoth; Arie Oksenberg
Journal:  Front Neurol       Date:  2014-07-17       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.